ECTE -  USA Stock  

USD 0.0002  0.00  0.00%

ECHO THERAPEUTICS employes about 19 people. The company is managed by 6 executives with total tenure of roughly 35 years, averaging almost 5.0 years of service per executive having 3.17 employees per reported executive. Evaluation of ECHO THERAPEUTICS management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with ECHO THERAPEUTICS INC future performance.
Continue to Investing Opportunities.


  Scott Hollander  CEO
CEO and President and Director



ECHO THERAPEUTICS Management Team Effectiveness

ECHO THERAPEUTICS INC has return on total asset (ROA) of (359.77) % which means that it has lost $359.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (3.649) %, meaning that it created substantial loss on money invested by shareholders. ECHO THERAPEUTICS management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Invested Capital is expected to grow to 8.68, whereas Return on Average Assets are forecasted to decline to (5.66) . ECHO THERAPEUTICS Current Assets are projected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 270,670. The current year Assets Non Current is expected to grow to about 465.9 K, whereas Goodwill and Intangible Assets are forecasted to decline to about 8.6 M.

ECHO THERAPEUTICS Quarterly Total Assets

1.08 MillionShare
The current year Issuance Purchase of Equity Shares is expected to grow to about 3.4 M, whereas Weighted Average Shares is forecasted to decline to about 10.9 M.

ECHO THERAPEUTICS Workforce Comparison

ECHO THERAPEUTICS INC is rated # 5 in number of employees category among related companies. The total workforce of Medical Devices industry is currently estimated at about 8,655. ECHO THERAPEUTICS adds roughly 19.0 in number of employees claiming only tiny portion of all equities under Medical Devices industry.


Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ECHO THERAPEUTICS insiders, such as employees or executives, is commonly permitted as long as it does not rely on ECHO THERAPEUTICS's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ECHO THERAPEUTICS insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ECHO THERAPEUTICS Notable Stakeholders

An ECHO THERAPEUTICS stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ECHO THERAPEUTICS often face trade-offs trying to please all of them. ECHO THERAPEUTICS's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ECHO THERAPEUTICS's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Scott Hollander - CEO and President and DirectorProfile
Alan Schoenbart - CFOProfile
Michael Goldberg - DirectorProfile
Elazer Edelman - DirectorProfile
Christine Olimpio - Director of Investor Relations and Corporate CommunicationsProfile
Shepard Goldberg - DirectorProfile

About ECHO THERAPEUTICS Management Performance

The success or failure of an entity such as ECHO THERAPEUTICS INC often depends on how effective the management is. ECHO THERAPEUTICS management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ECHO THERAPEUTICS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ECHO THERAPEUTICS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(5.52) (5.66) 
Return on Average Equity(355.55) (364.91) 
Return on Invested Capital 8.05  8.68 
Return on Sales(234.85) (253.39) 
Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. The company was founded in 1989 and is headquartered in Iselin, New Jersey. Echo Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 19 people.
The data published in ECHO THERAPEUTICS's official financial statements usually reflect ECHO THERAPEUTICS's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ECHO THERAPEUTICS INC. For example, before you start analyzing numbers published by ECHO THERAPEUTICS accountants, it's critical to develop an understanding of what ECHO THERAPEUTICS's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of ECHO THERAPEUTICS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ECHO THERAPEUTICS's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ECHO THERAPEUTICS's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ECHO THERAPEUTICS INC. Please utilize our Beneish M Score to check the likelihood of ECHO THERAPEUTICS's management to manipulate its earnings.

ECHO THERAPEUTICS Workforce Analysis

Traditionally, organizations such as ECHO THERAPEUTICS use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ECHO THERAPEUTICS within its industry.

ECHO THERAPEUTICS Manpower Efficiency

Return on ECHO THERAPEUTICS Manpower

Revenue Per Employee269
Revenue Per Executive853
Net Loss Per Employee657.9 K
Net Loss Per Executive2.1 M
Continue to Investing Opportunities. Note that the ECHO THERAPEUTICS INC information on this page should be used as a complementary analysis to other ECHO THERAPEUTICS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Tools for ECHO THERAPEUTICS Stock

When running ECHO THERAPEUTICS INC price analysis, check to measure ECHO THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ECHO THERAPEUTICS is operating at the current time. Most of ECHO THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of ECHO THERAPEUTICS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ECHO THERAPEUTICS's price. Additionally, you may evaluate how the addition of ECHO THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
CEO Directory
Screen CEOs from public companies around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites